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ABSTRACT
HIV serostatus disclosure plays an important role in HIV transmission risk reduction and is positively
associated with HIV medication adherence and treatment outcomes. However, to date, no study has
quantified the role of disclosure across the HIV treatment cascade, particularly in Sub-Saharan
Africa. We used data from a cohort of HIV-infected adults in Northern Tanzania to describe
associations between disclosure and engagement and retention in the HIV treatment cascade.
Between 2008 and 2009, the Coping with HIV/AIDS in Tanzania (CHAT) study enrolled 260 clients
newly diagnosed with HIV and 492 HIV-infected patients in established HIV care in two large HIV
care and treatment centers in Northern Tanzania. Participants aged 18 and older completed
annual clinical assessments and twice-annual in-person interviews for 3.5 years. Using logistic
regression models, we assessed sociodemographic correlates of HIV serostatus disclosure to at
least one household member, and associations between this disclosure measure and linkage to
care, evaluation for antiretroviral therapy (ART) eligibility, ART coverage, and rates of
undetectable HIV RNA levels during the follow-up period. Married individuals and those
diagnosed earlier were more likely to have disclosed their HIV infection to at least one
household member. During follow-up, HIV serostatus disclosure was associated with higher rates
of linkage to care, evaluation for ART eligibility, and ART coverage. No significant association was
observed with rates of undetectable viral loads. Marginal effects estimates suggest that a 10
percentage-point lower probability of linkage to care for those who did not disclose their HIV
serostatus (86% vs. 96%; p = 0.035) was compounded by an 18 percentage-point lower
probability of ever receiving a CD4 count (62% vs. 80%; p = .039), and a 20 percentage-point
lower probability of ever receiving ART (55% vs. 75%; p = .029). If causal, these findings suggest
an important role for disclosure assistance efforts across the HIV treatment cascade.
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Introduction
Approximately 71% of persons living with HIV, or 24.7
million, are in Sub-Saharan Africa (SSA) (UNAIDS,
2014). Impressively, the number of AIDS-related deaths
in SSA fell by 39% between 2005 and 2013 (UNAIDS,
2014), with the decrease attributed to increased access
to antiretroviral therapy (ART) (UNAIDS, 2014). How-
ever, recent estimates suggest that only as few as 13% of
infected persons initiated and have been retained on
ART (Okeke, Ostermann, & Thielman, 2014).
The HIV treatment cascade is a framework designed
to describe the steps necessary for effective treatment,
from being tested for HIV, linked to care, retained in
care, prescribed antiretroviral therapy, to attaining viro-
logic suppression (AIDS.gov & U.S. Department of
Health & Human Services, 2014; De Cock, 2014). As
treatment options continue to expand in SSA and else-
where, understanding barriers and facilitators of HIV
care and treatment across the treatment cascade is criti-
cal in order to maximize the efficacy of HIV care
programs.
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HIV serostatus disclosure plays an important role in
HIV transmission risk reduction and numerous studies
have described associations between disclosure and
elements of the HIV treatment cascade. Systematic
reviews identified fear of disclosure as an important
barrier to linkage to care (Govindasamy, Ford, & Kran-
zer, 2012) and highlighted the role of disclosure as an
enabling factor in ART initiation, adherence, and reten-
tion (Hodgson et al., 2014). Several additional studies
have described associations between HIV serostatus dis-
closure and virologic suppression (Labhardt et al., 2014;
Muller, Bode, Myer, Stahl, & von Steinbuchel, 2011;
Ramadhani et al., 2007; Teshome Yimer & Yalew,
2015). However, no study to date has quantified the
role of disclosure across the elements of the HIV treat-
ment cascade.
This analysis of HIV-infected Tanzanian adults exam-
ines associations of HIV serostatus disclosure to house-
hold members with indicators of linkage to care and
treatment outcomes across the HIV treatment cascade.
Specifically, in a cohort of persons newly diagnosed
with HIV we explore the associations between disclosure
and linkage to care, obtaining a CD4+ lymphocyte count
(used in this context as an indicator of ever being evalu-
ated for ART eligibility), and ART coverage; and in a
cohort of patients in established care we explore associ-
ations with sustained virologic suppression.
Methods
Study participants
From November 2008 to October 2009, the Coping with
HIV/AIDS in Tanzania (CHAT) observational cohort
study sequentially enrolled 260 individuals newly diag-
nosed with HIV at voluntary HIV counseling and testing
sites in Moshi, Tanzania, and randomly selected 492 HIV
patients in established care at the regional public hospital
or the private zonal referral hospital. Eligible participants
were ages 18 and above. The goal of the CHAT study was
to examine the influence of demographic and psychoso-
cial characteristics on risk behaviors, health services util-
ization, and health outcomes among HIV-infected
persons in Tanzania. The detailed sampling approach
and study cohort characteristics have been previously
described (Belenky et al., 2014; Ostermann et al., 2014;
Pence et al., 2012; Thielman et al., 2014).
Data collection
Participants completed in-person interviews every
6 months for 3.5 years. Interviews, conducted in Kiswahili,
assessed demographic and health characteristics, HIV
treatment history, including linkage to care and ART,
and HIV serostatus disclosure. Clinical assessments
were conducted annually and included viral loadmeasure-
ments for participants on ART and a review of
participants’ CD4+ lymphocyte counts from medical
records.
Measures
HIV serostatus disclosure after 3.5 years was assessed
using the question “How many of the people living
with you in your household know that you are HIV
positive?” Owing to variation in household sizes,
responses were recoded to a binary variable indicating
disclosure to at least one household member. While
this indicator captures only a single dimension of dis-
closure and cannot characterize the complex processes
involving the timing, means, intent, or targets of dis-
closure, it could be uniformly constructed across
diverse living arrangements and household sizes, and
thus used to analyze systematic variation in outcomes
across participants.
Three elements of the HIV treatment cascade charac-
terized newly diagnosed participants’ engagement in
HIV care. First, the 3.5-year follow-up assessment
included a review of all HIV care and treatment centers
(CTCs) participants had ever attended. Linkage to care
was defined as any visit to any CTC during the study
period. Second, the availability of any CD4+ lymphocyte
count was used as an indicator of whether newly diag-
nosed individuals had ever been evaluated for ART eligi-
bility. Third, self-reports at the 3.5-year follow-up
interview were used to describe whether individuals
had ever been on ART.
For patients enrolled into the study while in estab-
lished HIV care and who were on ART at least 6 months
prior to baseline, virologic suppression was assessed by a
binary variable describing whether patients had a consist-
ently undetectable viral load, defined as all HIV RNA
measurements during the study period below the detect-
able threshold of 150 copies/ml. This variable definition
was chosen to account for variable patterns of participant
follow-up and re-entry into the study and low rates of
virologic failure at individual assessments.
Other characteristics, evaluated at baseline, included
age, gender, education, rural vs. urban residence, time
since diagnosis, number of lifetime partners, lifetime
reports of commercial sex, physical and mental health
as measured by the Short-Form 8 health survey (Ware,
Kosinski, Dewey, & Gandek, 2001) and a composite
score summarizing participants’ agreement with 12
stigma questions (Visser, Makin, Vandormael, Sikkema,
& Forsyth, 2009).
60 J. OSTERMANN ET AL.
Analysis
Descriptive statistics and multivariate logistic regression
analysis were used to describe differences in disclosure
rates between newly diagnosed individuals and those in
established care, correlates of disclosure through the
end of the 3.5-year study period, and associations
between disclosure and the elements of the treatment
cascade. Student’s t-tests and Fisher’s exact tests assessed
the significance of bivariate associations; multivariate
regression models were estimated with robust standard
errors.
Ethics statement
Study activities were approved by the Kilimanjaro Chris-
tian Medical Center Institutional Review Board (IRB) in
Tanzania and the Duke University Health System IRB in
the USA. Written informed consent was obtained from
all participants.
Results
Table 1 summarizes participant characteristics at base-
line, rates of HIV serostatus disclosure, and correlates
of disclosure over time. Of 260 newly diagnosed partici-
pants, 175 were observed at the 3.5-year follow-up
assessment. Among 492 patients in established care,
435 completed the final assessment.
Newly diagnosed individuals and patients in estab-
lished care exhibited significant differences in disclos-
ure rates, both at enrollment (p < .001) and after 3.5
years of follow-up (p = .015). Among newly diagnosed
individuals, rates of disclosure increased from 45% to
75% during the study period; among patients in estab-
lished care rates increased from 74% to 84%. There
was little systematic variation in disclosure with par-
ticipant characteristics. Being married, time since
diagnosis, and treatment at the regional public hospi-
tal (as opposed to the private zonal referral hospital)
were associated with an increased likelihood of
disclosure.
Figure 1 and Table 2 show significant associations
between disclosure and three of the four elements of
the HIV treatment cascade evaluated. In bivariate ana-
lyses, rates of linkage to care, evaluation for ART eligi-
bility, and ART coverage were higher among newly
diagnosed individuals who reported disclosure to at
least one household member. In multivariate analyses,
disclosure to at least one household member was associ-
ated with higher rates of linkage to care (OR 4.75; 95% CI
[1.11–20.26]; p = .035), assessment of ART eligibility
(OR 2.60; [1.12–6.04]; p = .039) and ever having been
on ART (OR 2.56; [1.13–5.79]; p = .029) during the
3.5-year follow-up period. Disclosure was not signifi-
cantly associated with maintaining a consistently sup-
pressed viral load among persons in established care
and on ART at study enrollment.
Table 1. Participant characteristics at enrollment and HIV serostatus disclosure over time.
Newly diagnosed In established care Correlates of disclosurea,c
Mean (sd) or N (%) Mean (sd) or N (%) OR [95% CI]
Number of participants At baseline 260 492 733
After 3.5 years 175 435
Gender Female (vs. male) 179 (68.8%) 335 (68.1%) 0.81 [0.52–1.27]
Age In years 37.4 (8.9) 41.8 (8.8) *** 1.01 [0.99–1.03]
Education Any secondary (vs. primary or less) 33 (12.7%) 100 (20.3%) 0.80 [0.48–1.33]
Marital status Married (vs. all others) 98 (37.7%) 181 (36.8%) 3.04 [1.98–4.65] ***
Residence Urban (vs. rural) 122 (46.9%) 239 (48.6%) 0.89 [0.62–1.28]
Time since diagnosis (years) 0.4 (1.5) 2.6 (2.0) *** 1.16 [1.02–1.33] *
SF-8 composite scores Physical health 44.1 (11.5) 49.4 (8.7) *** 1.01 [0.98–1.03]
Mental health 47.7 (10.5) 52.6 (7.5) *** 1.00 [0.97–1.02]
Stigma score (higher is worse) 0.5 (0.4) 0.5 (0.3) 0.96 [0.56–1.64]
Lifetime partners 1–2 89 (34.4%) 224 (46.0%) ** Ref
3–4 92 (35.5%) 128 (26.3%) 1.39 [0.88–2.20]
5 or more 78 (30.1%) 135 (27.7%) 1.42 [0.88–2.30]
Commercial sex Ever (vs. never) 92 (35.4%) 84 (17.1%) 1.04 [0.66–1.63]
Enrollment location Hospital (vs. community VCT site) 149 (57.3%) Ref
Treatment location Regional public hospital 224 (45.5%) 1.84 [1.08–3.15] *
Private zonal referral hospital 149 (57.3%) 1.39 [0.71–2.70]
Disclosed HIV status to at least one household member
… at baselinea 107 (45.3%) 338 (73.5%) ***
… after 3.5 yearsa,b 115 (74.7%) 343 (83.7%) *
aExcludes participants in single-person households.
bExcludes loss to follow-up; see Table 2.
cDisclosure as of the last round observed; association evaluated using logistic regression with robust standard errors.
*Statistical significance at the 0.05 level.
**Statistical significance at the 0.01 level.
***Statistical significance at the 0.001 level.
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Discussion
In a cohort of Tanzanian adults who were newly diag-
nosed with HIV infection, serostatus disclosure to at
least one household member during a 3.5-year follow-
up period was associated with higher rates of linkage to
care, evaluation for ART eligibility, and ART treatment.
While the causality of the observed associations could
not be evaluated, the marginal effects estimates from
Figure 1. HIV serostatus disclosure and engagement in HIV care during a 3.5-year follow-up period. Note: Statistical significance
assessed using Fisher’s exact test. 1Consistently undetectable viral load, threshold of 150 cells/mm3, in up to 4 assessments at baseline,
12, 24 and 36 months, fewer in the case of loss to follow-up; among participants who were on ART at least 180 days prior to enrollment.
Table 2. HIV serostatus disclosure and retention in the HIV treatment cascade during a 3.5-year follow-up period.
Ever linked to care Ever had a CD4 count Ever on ART Undetectable viral load c
(A) Number of participants (%)
Study cohort Enrolled after a new HIV diagnosis In established care
Number of study participants enrolled N = 260 N = 492
Number of participants lost to follow-up 85 (32.6%) 57 (11.6%)
Exclusion criterion – Never linked to care Never linked to care Not on ART
Met exclusion criterion – 9 (3.5%) 9 (3.5%) 126 (25.6%)
No other persons in the household 21 (8.1%) 21 (8.1%) 21 (8.1%) 19 (3.9%)
Missing data on key variables a - - 12 (4.6%) 5 (1.0%)
Number of observations included in analyses N = 154 N = 145 N = 145 N = 285
(B) Retention in the HIV treatment cascade
Ever linked to care 145 (94.2%)
Ever had a CD4 count 110 (75.9%)
Ever on ART 102 (70.3%)
Consistently undetectable viral load 221 (77.5%)
(C) Multivariate associationsb
With characteristics at enrollment
Age 1.17 [1.03–1.32]* 1.05 [1.00–1.10] 1.04 [0.99–1.09] 1.01 [0.98–1.05]
Female 3.78 [0.85–16.75] 1.15 [0.45–2.89] 0.50 [0.18–1.39] 0.93 [0.47–1.83]
Secondary education 0.61 [0.09–4.08] 0.83 [0.24–2.86] 0.88 [0.28–2.81] 1.39 [0.65–2.97]
Married 0.48 [0.09–2.60] 0.95 [0.41–2.20] 1.20 [0.53–2.73] 0.73 [0.40–1.34]
Urban residence 1.18 [0.26–5.31] 1.13 [0.50–2.57] 1.27 [0.59–2.76] 1.30 [0.74–2.29]
With HIV serostatus disclosure at follow-up
Disclosed to at least one household member 4.75 [1.11–20.26]* 2.6 [1.12–6.04]* 2.56 [1.13–5.79]* 1.10 [0.50–2.42]
Note: Fewer in the case of loss to follow-up; among participants who were on ART at least 180 days prior to enrollment. 230 participants (81%) had 4 assessments;
42 (15%) had 3 assessments; 7 (2%) had 2 assessments and 6 (2%) had 1 assessment.
aMissing data on ART coverage or date of initiation of ART, respectively.
bOdds ratios with 95% confidence intervals from multivariate logistic regression models.
cConsistently undetectable viral load, threshold of 150 cells/mm3, in up to 4 assessments at baseline, 12, 24 and 36 months.
*Statistical significance at the 0.05 level.
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the estimated models suggest that participants who did
not disclose their HIV serostatus had a 10 percentage-
point lower probability of linkage to care (86% vs. 96%;
p = .035), compounded by an additional 18 percen-
tage-point lower probability of ever receiving a CD4
count (62% vs. 80%; p = .039), and a 20 percentage-
point lower probability of ever receiving ART (55% vs.
75%; p = .029) during the 3.5-year follow-up period.
The findings are consistent with theoretical models of
disclosure (Qiao, Li, & Stanton, 2013) and prior evidence
on the role of stigma and fears of disclosure in limiting
uptake and continuation of HIV treatment (Duff, Kipp,
Wild, Rubaale, & Okech-Ojony, 2010; Hodgson et al.,
2014; Medley, Garcia-Moreno, McGill, & Maman,
2004; Turan & Nyblade, 2013; Wolf et al., 2014). In con-
junction with other literature on associations between
disclosure, ART adherence, and virologic outcomes,
and with appropriate caution regarding causal interpret-
ations, these findings support further research on the
positive impact that disclosure may have on HIV treat-
ment outcomes.
We acknowledge several limitations. First, causal
pathways of the observed associations could not be
established. Second, selective loss to follow-up may
have biased our estimates. Third, estimates may not be
representative of other populations. Finally, by relying
on basic dichotomous measures of disclosure and reten-
tion in the treatment cascade the study is unable to
characterize the complexity underlying the observed
relationships. The results thus lack detailed information
that may inform disclosure interventions (Dima, Stutter-
heim, Lyimo, & de Bruin, 2014; Kennedy, Fonner, Arm-
strong, O’Reilly, & Sweat, 2015). CHAT was not
designed or sufficiently powered to characterize the
mechanisms underlying the observed associations.
Conclusion
Disclosure was associated with improved linkage to care,
assessment for ART eligibility, and ART initiation,
although not long-term viral suppression. If causal, these
findings would suggest that efforts to support HIV-
infected individuals in disclosure may have the potential
to improve outcomes across the HIV treatment cascade.
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